Shiloh
Editor, Senior Moderator
Source: https://www.scmp.com/news/china/sci...chinas-sinopharm-weaker-against-omicron-study
Covid-19 booster from China’s Sinopharm is weaker against Omicron, study finds
The jab shows significantly weaker neutralising activity against the variant than against an older strain, researchers say
The vaccine’s neutralising activity eight to nine months after a second dose ‘declined rapidly and could hardly be detected’, making a third dose necessary
Phoebe Zhang
Published: 9:34pm, 20 Dec, 2021
Updated: 9:44pm, 20 Dec, 2021
A Covid-19 vaccine booster shot by China’s Sinopharm showed significantly weaker neutralising activity against the Omicron variant than for an older coronavirus strain from Wuhan, Chinese researchers found.
Researchers from Shanghai Jiao Tong University and the Institute of Respiratory Diseases said that they had assessed samples from 292 health care workers given a third shot eight to nine months after their second, in a study published on Saturday on preprint server medRxiv.
The study, which has not been peer-reviewed, found that the neutralising antibody activity of a Sinopharm BBIBP-CorV booster against Omicron showed a 20.1-fold reduction.
Given that Omicron is the most divergent so far of the coronavirus variants, there are concerns that it could evade the immunity given by existing vaccines and cause a large number of breakthrough infections. Waning immunity and viral diversification both create a potential need for further boosters, the study report said...
Covid-19 booster from China’s Sinopharm is weaker against Omicron, study finds
The jab shows significantly weaker neutralising activity against the variant than against an older strain, researchers say
The vaccine’s neutralising activity eight to nine months after a second dose ‘declined rapidly and could hardly be detected’, making a third dose necessary
Phoebe Zhang
Published: 9:34pm, 20 Dec, 2021
Updated: 9:44pm, 20 Dec, 2021
A Covid-19 vaccine booster shot by China’s Sinopharm showed significantly weaker neutralising activity against the Omicron variant than for an older coronavirus strain from Wuhan, Chinese researchers found.
Researchers from Shanghai Jiao Tong University and the Institute of Respiratory Diseases said that they had assessed samples from 292 health care workers given a third shot eight to nine months after their second, in a study published on Saturday on preprint server medRxiv.
The study, which has not been peer-reviewed, found that the neutralising antibody activity of a Sinopharm BBIBP-CorV booster against Omicron showed a 20.1-fold reduction.
Given that Omicron is the most divergent so far of the coronavirus variants, there are concerns that it could evade the immunity given by existing vaccines and cause a large number of breakthrough infections. Waning immunity and viral diversification both create a potential need for further boosters, the study report said...
